I-Mab to Hold Investor Call to Report Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab

SHANGHAI and GAITHERSBURG,MD.,May 19,2022 -- I-Mab (the "Company") (Nasdaq" IMAB),a clinical-stage biopharmaceutical company committed to the discovery,development and commercialization of novel biologics,today announced that it will hold a call with investors at 8a.m. EST on May27thto present preliminary data from an ongoing phase 2 clinical trial of its differentiated CD73 antibody uliledlimab (also known as TJD5,or TJ004309) and the global clinical development plan.

I-Mab Conference Call Information

Investors and analysts are invited to join the conference call at 8 a.m. EST on May 27th via Zoom:

Meeting URL: https://i-mabbiopharma.zoom.us/j/84961586624?pwd=TVQ0SUtyMUl6d2dZbHgybGVScGwvUT09

Meeting ID: 849 6158 6624

Password: 160619

About Uliledlimab (TJD5)

Uliledlimab (TJD5) is a differentiated,humanized antibody against CD73,an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine. Adenosine in turn binds to adenosine receptors on relevant immune cells and inhibits anti-tumor immune responses in tumor microenvironment. Uliledlimab is expected to offer clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies. Uliledlimab is effective in anti-tumor activities through a unique intra-dimer binding,leading to differentiated and favorable functional properties as evident in preclinical studies.

About I-Mab

I-Mab (Nasdaq: IMAB) is an innovation-driven global biopharma company focused on the discovery,development and commercialization of novel and highly differentiated biologics for immuno-oncology diseases. The Company's mission is to bring transformational medicines to patients around the world through innovation. I-Mab's globally competitive pipeline of more than 20 clinical and preclinical-stage drug candidates is driven by its internal discovery and global partnerships for in-licensing,based on the Company's Fast-to-Proof-of-Concept and Fast-to-Market development strategies. The Company is progressing from a clinical-stage biotech company into an innovative global specialty biopharmaceutical company with cutting-edge R&D capabilities,a world-class GMP manufacturing facility,and commercial capability. I-Mab has established its global footprint in Shanghai (headquarters),Beijing,Hangzhou,Guangzhou,Lishui and Hong Kong in China,and Maryland and San Diego in the United States. For more information,please visit http://www.i-mabbiopharma.comand follow I-Mab on LinkedIn,Twitter,and WeChat.

I-Mab Contacts

Richard Yeh

Chief Operating Officer

IR@i-mabbiopharma.com

Gigi Feng

Chief Communications Officer

PR@i-mabbiopharma.com

Investor Inquiries:

The Piacente Group,Inc.

Emilie Wu

E-mail:emilie@thepiacentegroup.com

Office line: +86 21 6039 8363

View original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-to-hold-investor-call-to-report-latest-phase-2-clinical-data-of-its-differentiated-cd73-antibody-uliledlimab-301551022.html